VISCHER advised Ikerian on the deal. Ikerian AG and its subsidiary, RetinAI U.S. Inc., a leading developer of software solutions for medical image and data management,...
You must be a Standard 1 Year member to access this content.
VISCHER advised Mininavident AG on the deal. Mininavident AG, in Liestal, developer and manufacturer of the world’s smallest dynamic navigation system for dental implant placement, was...
You must be a Standard 1 Year member to access this content.
VISCHER advised Ysios Capital and Kurma Partners. Memo Therapeutics AG, a late-stage biotech company developing a best-in-class BKV-neutralizing anti-body for BKV infection in kidney transplantation, raised...
You must be a Standard 1 Year member to access this content.
VISCHER AG acted for Odne on the deal. Swiss dental startup Odne (former Lumendo) has raised USD 5.5m to fund the upcoming US market launch for...
You must be a Standard 1 Year member to access this content.
VISCHER acted for Artiria Medical SA on the deal. Artiria Medical SA, a Swiss neurovascular MedTech company developing next-generation neuro-interventional products for stroke and aneurysms, closed...
You must be a Standard 1 Year member to access this content.
Vischer advised GlycoEra AG on the deal. GlycoEra AG has closed CHF 45m (USD 49m) Series A financing round, co-led by re-nowned US and European life...
You must be a Standard 1 Year member to access this content.
VISCHER advised Proteomedix on the deal. Proteomedix AG, a Swiss private, commercial-stage diagnostics oncology company and Water Biotech, Inc. (Nasdaq: BWV) are forming together a company...
You must be a Standard 1 Year member to access this content.
Walder Wyss advised the investors while VISCHER acted as legal advisor to Nouscom in the transaction. Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized...
You must be a Standard 1 Year member to access this content.
VISCHER advised Memo Therapeutics on the financing. Memo Therapeutics AG, a late-stage biotech company developing best-in-class therapeutic antibodies closed a CHF25 million series C financing round...
You must be a Standard 1 Year member to access this content.
VISCHER acted as legal advisor to LimmaTech Biologics in the transaction. LimmaTech Biologics AG closed a USD 37m (CHF 33m) Series A financing round co-led by Adjuvant...
You must be a Standard 1 Year member to access this content.
VISCHER advises Mosanna Therapeutics on the deal. Mosanna Therapeutics AG closes an extension of the Seed Financing Round with the investors Supermoon Capital and High-Tech Gründerfonds...
You must be a Standard 1 Year member to access this content.
VISCHER AG advises Bachem Holding on the offering. Bachem Holding AG (SIX: BANB) has successfully raised CHF 108.1 million through the placement of 1’250’000 new registered...
You must be a Standard 1 Year member to access this content.
